Brokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) PT at $11.00

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.00.

Several brokerages have issued reports on AQST. Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Aquestive Therapeutics by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after purchasing an additional 90,543 shares during the period. State Street Corp lifted its stake in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP boosted its position in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Aquestive Therapeutics by 4.9% in the third quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock valued at $4,598,000 after buying an additional 42,800 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at $594,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Trading Down 3.8 %

AQST opened at $3.52 on Friday. Aquestive Therapeutics has a twelve month low of $1.95 and a twelve month high of $6.23. The firm has a market capitalization of $320.95 million, a PE ratio of -7.82 and a beta of 2.62. The firm’s 50-day moving average price is $4.61 and its 200 day moving average price is $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter in the prior year, the company posted ($0.03) EPS. As a group, analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.